<?xml version="1.0" encoding="UTF-8"?>
<ref id="bb0225">
 <label>44</label>
 <element-citation publication-type="journal" id="rf0215">
  <person-group person-group-type="author">
   <name>
    <surname>Sanchez-Luna</surname>
    <given-names>M.</given-names>
   </name>
   <name>
    <surname>Burgos-Pol</surname>
    <given-names>R.</given-names>
   </name>
   <name>
    <surname>Oyaguez</surname>
    <given-names>I.</given-names>
   </name>
   <name>
    <surname>Figueras-Aloy</surname>
    <given-names>J.</given-names>
   </name>
   <name>
    <surname>Sanchez-Solis</surname>
    <given-names>M.</given-names>
   </name>
   <name>
    <surname>Martinon-Torres</surname>
    <given-names>F.</given-names>
   </name>
  </person-group>
  <article-title>Cost-utility analysis of Palivizumab for Respiratory Syncytial Virus infection prophylaxis in preterm infants: update based on the clinical evidence in Spain</article-title>
  <source>BMC Infect Dis</source>
  <volume>17</volume>
  <issue>1</issue>
  <year>2017</year>
  <fpage>687</fpage>
  <ext-link ext-link-type="uri" xlink:href="pmid:29041909" id="ir0295" xmlns:xlink="http://www.w3.org/1999/xlink">29041909</ext-link>
  <comment>PMCPMC5645982</comment>
  <pub-id pub-id-type="pmid">29041909</pub-id>
 </element-citation>
</ref>
